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Objectives This study sought to compare use of evidence-based secondary preventive medications after coronary bypass
surgery (CABG) and percutaneous coronary intervention (PCI).
Background Use of cardioprotective medication after coronary revascularization has been inconsistent and relatively low in
older studies.
Methods We studied patients in a large integrated healthcare delivery system who underwent CABG or PCI for new onset
coronary disease. We used data from health plan databases about prescriptions dispensed during the first year
after initial coronary revascularization to identify patients who never filled a prescription and to calculate the
medication possession ratio among patients who filled at least 1 prescription. We focused on angiotensin-
converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), beta-blockers, and statins.
Results Between 2000 and 2007, 8,837 patients with new onset coronary disease underwent initial CABG, and 14,516
underwent initial PCI. Patients receiving CABG were more likely than patients receiving PCI to not fill a prescrip-
tion for a statin (7.1% vs. 4.8%, p  0.0001) or for an ACEI/ARB (29.1% vs. 22.4%, p  0.0001), but similar
proportions never filled a prescription for a beta-blocker (6.4% vs. 6.1%). Among those who filled at least 1 pre-
scription post-revascularization, patients receiving CABG had lower medication possession ratios than patients
receiving PCI for ACEI/ARBs (69.4% vs. 77.8%, p  0.0001), beta-blockers (76.1% vs. 80.6%, p  0.0001), and
statins (82.7% vs. 84.2%, p  0.001).
Conclusions Patients who received CABG were generally less likely than patients who received PCI to fill prescriptions for sec-
ondary preventive medications and to use those medications consistently in the first year after the
procedure. (J Am Coll Cardiol 2013;61:295–301) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.10.018Coronary revascularization does not affect the underlying
disease process of coronary atherosclerosis, so medical ther-
apy is routinely recommended after coronary artery bypass
graft (CABG) surgery or percutaneous coronary interven-
tion (PCI). Medications that reduce the rate of death or
subsequent myocardial infarction (MI) in patients with
coronary disease include antiplatelet drugs, beta-blockers,
angiotensin converting enzyme inhibitors (ACEI), angio-
tensin II receptor blockers (ARBs), and lipid-lowering
therapy, particularly statins in appropriate patients. Use of
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accepted October 22, 2012.these agents is recommended as secondary prevention
among patients with clinically evident coronary artery dis-
ease (1), including patients who have undergone CABG or
PCI (2,3).
Roughly 838,000 patients underwent a CABG or PCI in
2009 in the United States (4). Patients who have undergone
coronary revascularization might not, however, fill an initial
prescription for secondary preventive medications or use
these medications consistently, especially after a CABG
(5–10). Patients who have undergone successful coronary
revascularization might not use recommended medications
consistently for several reasons, including a belief that
cardiac medications are no longer important once a coronary
obstruction has been treated mechanically. We hypothe-
sized that patients who have undergone CABG would be
less likely than patients who have undergone PCI to take
secondary prevention medications. We tested this hypoth-
esis in a large cohort of patients from an integrated health
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of cardiovascular preventive ther-
apies and that charges minimal
copayments to fill prescriptions
at health plan pharmacies.
Methods
Source population and study
cohort. Kaiser Permanente North-
ern California is a large, integrated
healthcare delivery system that
provides care to more than 3.2
million individuals in the greater
San Francisco Bay Area who are
broadly representative of the lo-
cal and statewide population,
apart from slightly lower repre-
sentation of the extremes of age
and income (11). We con-
structed a cohort of patients with
incident coronary artery disease who received CABG or
PCI as an initial coronary revascularization strategy. We
identified all health plan members 30 years of age or older
who received an initial CABG or PCI procedure between
January 1, 2000, through December 31, 2007 (International
Classification of Diseases-Ninth Edition [ICD-9] codes
00.66, 36.0, 36.00, 36.01, 36.02, 36.05, 36.06, 36.07, 36.09,
36.10, 36.11, 36.12, 36.13, 36.14, 36.15, 36.16, 36.17, and
36.19; and Current Procedure Terminology–Fourth Edi-
tion codes 33510, 33511, 33512, 33513, 33514, 33516,
33517, 33518, 33519, 33521, 33522, 33523, 33530, 33533,
33534, 33535, 33536, 33572, 92973, 92980, 92981, 92982,
92984, 92995, and 92996). We assigned the index date as
the date of the revascularization procedure. To capture
complete data on demographic characteristics, comorbidi-
ties, and concurrent medication use, we restricted the
analysis to patients with complete demographic data and at
least 12 months of continuous membership and continuous
pharmacy benefit before the index date. We excluded
patients with a history of coronary artery disease, coronary
revascularization, maintenance renal dialysis, organ trans-
plantation, missing membership information after the index
date, or unconfirmed index hospital stay.
This study was approved by the institutional review
boards of the Kaiser Foundation Research Institute and of
Stanford University. Waiver of informed consent was ob-
tained because of the nature of the study.
Medication adherence. We ascertained baseline and lon-
itudinal medication use from pharmacy records with pre-
iously validated methods (12,13). Medications of interest
ncluded statins, beta-blockers, ACEIs, ARBs, and clopi-
ogrel. We did not assess use of aspirin, because it can be
btained without a prescription and, therefore, complete
nformation on its use was not available. We computed the
Abbreviations
and Acronyms
ACEI  angiotensin
converting enzyme inhibitor
ARB  angiotensin
receptor blocker
CABG  coronary artery
bypass graft surgery
CKD  chronic kidney
disease
HF  heart failure
ICD-9  International
Classification of Diseases-
Ninth Edition
MI  myocardial infarction
MPR  medication
possession ratio
PCI  percutaneous
coronary interventionedication possession ratio (MPR) over the first 12 monthsafter the index date, among those who received at least 1
prescription for the drug of interest after initial revascular-
ization. Patients were assumed to have continuous coverage
for a given medication from the date they filled the initial
prescription until the end of the final prescription, as long as
there were no gaps in coverage of 30 days or more. When a
gap in coverage 30 days was noted, patients were consid-
ered uncovered from the last day of the final filled prescrip-
tion until the date their next prescription was filled or the
end of follow-up at 12 months after revascularization. For
example, a patient with a single 2-week gap between
prescription refills was assumed to have a 100% MPR,
whereas a patient with a single 6-week gap during the year
would have an MPR of 88% (46 of 52), and a patient who
filled a single 30-day prescription during the year would
have an MPR of 8% (30 of 365).
Because medication adherence might change over long-
term follow-up, we analyzed MPR over the fixed time
interval of 1 year after the index date. We required that each
patient have at least 1 full year of follow-up to permit the
MPR to be calculated over the same period of follow-up for
all patients.
Covariates. We obtained data on age, sex, self-reported
race/ethnicity, and treatment facility from health plan da-
tabases. We identified comorbid conditions up to 4 years
before the index date with previously validated approaches
on the basis of ICD-9 diagnosis and procedure codes and
Current Procedural Terminology–Fourth Edition proce-
dure codes identified from health plan hospital stay, ambu-
latory, laboratory, and pharmacy databases (14–20). We
ascertained the following covariates: smoking status and
history of heart failure, ventricular fibrillation/tachycardia,
ischemic stroke/transient ischemic attack, peripheral arterial
disease, valvular heart disease, rheumatic heart disease, atrial
fibrillation/flutter, diabetes mellitus, hypertension, dyslipi-
demia, arthritis, dementia, chronic liver disease, chronic
lung disease, chronic kidney disease (CKD), diagnosed
depression, hyperthyroidism, hypothyroidism, systemic can-
cer, or hospitalized bleed. The criteria for defining these
covariates have been published previously (14–20). In brief,
a diagnosis of heart failure required at least 2 outpatient
visits with an ICD-9CM code for heart failure or an
inpatient admission with a primary diagnosis of heart
failure. CKD was defined as estimated glomerular filtration
rate of 60 ml/min/1.73 m2 or lower, on the basis of the
Chronic Kidney Disease Epidemiology Collaboration esti-
mating equation.
Statistical methods. We used multivariable regression
analysis to assess the relationship of CABG or PCI on
MPR, while adjusting for baseline covariates. We analyzed
non-use of medications (i.e., patients who never filled a
prescription for the medication of interest) with logistic
regression, and among patients who filled least 1 prescrip-
tion, we analyzed MPR as a continuous variable with
ordinary least-squares linear regression. Analyses were per-
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Development Team, Vienna, Austria).
Results
Between 2000 and 2007, a total of 28,477 patients with
new-onset coronary disease underwent initial coronary re-
vascularization in Kaiser Permanente Northern California.
After excluding patients who did not have a full year of
follow-up data available (1,486 who died, and 3,416 who
did not have continuous prescription drug coverage) and
222 patients receiving chronic dialysis, the final study
population consisted of 23,353 patients, 8,837 of whom
received an initial CABG, and 14,516 of whom received an
initial PCI. Patients who underwent CABG were some-
what older and less likely to have had a recent MI or
diagnosed depression than patients who underwent PCI
(Table 1). Patients who received CABG were also more
likely to have a history of diabetes, hypertension, dyslipide-
Baseline Characteristics of Patients With NewOn t Coron y Disease Undergoing Init al CABG or PCITable 1 B seline Characteristic of Pati nts With NewOnset Coronary Disease Undergoing Initial CABG or PCI
CABG
(n  8,837)
PCI
(n  14,516) p Value
Mean age (yrs) 67.3 10.0 64.0 11.2 0.0001
Male 76.6 71.1 0.0001
White race 79.4 77.8 0.005
Cardiovascular history
Acute myocardial infarction 11.9 30.3 0.0001
Unstable angina 10.2 12.3 0.0001
Heart failure 10.0 5.4 0.0001
Atrial fibrillation 8.6 6.2 0.0001
Cardiac risk factors
Current or former smoker 35.3 34.4 0.16
Diabetes mellitus 33.8 27.8 0.0001
Hypertension 63.5 55.7 0.0001
Dyslipidemia 87.2 82.7 0.0001
Comorbid conditions
Chronic kidney disease 33.0 27.2 0.0001
Stroke or TIA 3.0 2.6
Chronic lung disease 17.6 17.3 0.66
Chronic liver disease 0.8 1.3 0.0003
Systemic cancer 9.0 8.0 0.02
Depression 9.6 12.7 0.0001
Values are mean  SD or %.
CABG  coronary artery bypass graft surgery; PCI  percutaneous coronary intervention; TIA 
ransient ischemic attack.
Medication Use in the First Year After Initial CABG or PCITable 2 Medication Use in the First Year After Initial CABG or
No Prescription Filled
CABG PCI
Adjusted CABG
PCI OR (CI) p
ACEI/ARB 29.1 22.4 1.34 (1.25 to 1.43) 
Beta-blocker 6.4 6.1 0.81 (0.72 to 0.91) 
Statin 7.1 4.8 1.18 (1.04 to 1.33) 
Clopidogrel 88.5 4.9 149 (134 to 165) *p value in fully adjusted model, coronary artery bypass grafting (CABG) compared with percutaneous co
ACEI  angiotensin converting enzyme inhibitor; ARB  angiotensin receptor blocker; CI  confidencemia, CKD, heart failure, and atrial fibrillation (Table 1). All
subsequent analyses were adjusted for differences in baseline
characteristics.
Most patients were treated with a statin in the first year
after coronary revascularization, but significantly more
CABG patients (7.1%) than PCI patients (4.8%) never
filled a prescription for a statin (Table 2). Among patients
who filled least 1 prescription for a statin, the MPR was
significantly lower among CABG patients (82.7%) than
among PCI patients (84.2%). The unadjusted difference of
1.5% in MPR was somewhat attenuated (to 1.0%) after
adjustment for baseline characteristics but remained statis-
tically significant (p  0.001).
Most patients were treated with a beta-blocker after
coronary revascularization, with a similar proportion of
CABG patients (6.4%) and PCI patients (6.1%) who never
filled a prescription (Table 2). After adjustment for baseline
confounding factors, however, CABG patients were signif-
icantly less likely than PCI patients to have never filled a
prescription for a beta-blocker. In contrast, among patients
who filled at least 1 prescription for a beta-blocker, CABG
patients had a significantly lower MPR (76.1%) than PCI
patients (80.6%). The unadjusted difference of 4.5% in
MPR was slightly attenuated (to 3.7%) but still significant
(p  0.0001) after adjusting for baseline characteristics.
The use of ACEI/ARBs after coronary revascularization
was more variable than that of statins and beta-blockers
(Table 2). A higher percentage of CABG patients (29.1%)
than of PCI patients (22.4%) never filled a prescription for
an ACEI or ARB in the year after revascularization (p 
0.0001). Among those who filled at least 1 prescription, the
MPR among CABG patients (69.4%) was lower than for
PCI patients (77.8%) over the first year. The unadjusted
difference of 8.4% in MPR between CABG and PCI
patients was essentially unchanged (8.2%) after multivari-
able adjustment for baseline characteristics and remained
statistically significant (p  0.0001).
We also examined use of clopidogrel between CABG or
PCI patients, to provide a context for interpreting the other
medication data. Most CABG patients (88.5%) did not fill
a prescription for clopidogrel, whereas only 4.9% of PCI
patients did not (p 0.0001). Among patients who filled at
least 1 prescription for clopidogrel, the MPR was much
lower among CABG patients (40.1%) than PCI patients
MPR in Patients With >1 Prescription
* CABG PCI
Adjusted CABG
PCI Difference (CI) p Value*
1 69.4 77.8 8.2 (7.3 to9.2) 0.0001
76.1 80.6 3.7 (2.9 to4.4) 0.0001
82.7 84.2 1.0 (0.4 to1.7) 0.001
1 40.1 54.5 9.2 (7.3 to11.1) 0.0001PCI
Value
0.000
0.001
0.009
0.000ronary intervention (PCI).
interval; MPR  medication possession ratio; OR  odds ratio.
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between CABG and PCI patients was somewhat attenuated
(to 9.2%) but remained significant after adjusting for base-
line characteristics (p  0.0001).
Subgroups. The lower use of secondary preventive medi-
cations among patients who had CABG was generally
consistent in key patient subgroups (Fig. 1). Among pa-
tients with diabetes mellitus or heart failure, there were
generally smaller gaps in use of secondary preventive med-
ications, particularly for ACEI/ARBs, between CABG-
and PCI-treated patients. The lower use of secondary
medications among CABG patients was generally consis-
tent among patients with or without CKD, lung disease,
liver disease, and a prior MI (Fig. 1).
Secular trends. Use of secondary preventive medications
increased progressively between 2000 and 2007. The per-
centage of patients who never filled a prescription for an
ACEI/ARB, beta-blocker, or statin declined progressively
(Fig. 2), and the gap between CABG and PCI narrowed
Figure 1 MPR in Subgroups
Differences in medication possession ratios (MPR), coronary artery bypass graft s
angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB
larization. CKD  chronic kidney disease; HF  heart failure; MI  myocardial infaover time for statins and beta-blockers but persisted for
ACEI/ARBs. Similarly, the MPR among patients with at
least 1 prescription rose steadily over time for all 3 medica-
tions; the gap between CABG and PCI narrowed slightly
for beta-blockers, persisted for statins, and widened for
ACEI/ARBs (Fig. 3).
Discussion
Use of medications for secondary prevention of coronary
artery disease after coronary revascularization was quite high
in this study. Nevertheless, patients who had undergone a
CABG were generally less likely than patients who under-
went a PCI to be started on statins and ACEI/ARBs and
less likely to refill their medications consistently during the
first year after revascularization. This gap in use of evidence-
based therapies, although small in absolute terms, suggests
there is an opportunity to further improve quality of care for
patients after coronary revascularization.
(CABG) patients minus percutaneous coronary intervention (PCI) patients, for
ta-blockers, and statins among clinical subgroups after initial coronary revascu-
.urgery
s), be
rction
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at the time of hospital discharge for a cardiovascular
diagnosis has become an important focus of quality im-
provement efforts. Prescription at the time of discharge is
under the control of physicians and health systems, and our
data show steady improvements in these rates over time
(Fig. 2), with little to no gap between CABG and PCI
patients for beta-blockers and statins in the final study year
(2007). Subsequent adherence to initially prescribed medi-
cations is not measured commonly and depends on patients
to refill and take their medications consistently. Use of
Figure 2 Trends in Mediation Use
Time trends in the percentage of patients who did not fill a prescription for ACEI/A
Abbreviations as in Figure 1.
Figure 3 Trends in Subgroups
Time trends in the medication possession ratio among patients who filled at least 1 pre
Abbreviations as in Figure 1.secondary preventive medications among patients who filled
an initial prescription also improved over time (Fig. 3), yet
MPRs were consistently lower after CABG than after PCI.
The reasons for this persistent gap are uncertain but might
be related to patterns of follow-up care, if patients are less
likely to visit a cardiologist for subsequent care after a
CABG than after a PCI and cardiologists are more likely to
prescribe and encourage use of preventive medications
(21,22). Furthermore, patients might feel that a CABG was
the definitive treatment of their coronary disease and hence
that medications are no longer necessary, whereas patients
eta-blockers, and statins in the first year after coronary revascularization.
on for ACEI/ARBs, beta-blockers, and statins after initial coronary revascularization.RBs, bscripti
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platelet agents, are important to maintain patency of the
stented area. Surveys of patients after CABG found that
they have concerns about the overuse and harms of prescrip-
tion drugs and that poor medication adherence was corre-
lated with social, economic, and demographic factors (23).
Further research is needed to understand the reasons for
discontinuation of medications after CABG or PCI and to
develop appropriate interventions, either at the health sys-
tem level (e.g., care protocols) or at the patient level (e.g.,
education on the importance of continued medical therapy).
This study was conducted in a large integrated health
system that provides medication with minimal copayments
and has pharmacies conveniently located in its medical
centers. Medication use might also be higher in the Kaiser
Permanente Northern California system because of its focus
on quality improvement and uniform electronic health
records. Other large, integrated delivery systems, such as the
Veterans Administration, also have higher levels of medi-
cation use after CABG (24). Medication use in less well-
integrated healthcare settings is likely to be much lower,
particularly if care is fragmented or patients have to make
large payments for prescription drugs. These differences
might particularly affect long-term adherence and the fre-
quency of prescription refills.
Prior studies have usually measured prescriptions for
evidence-based medications at the time of hospital dis-
charge (25,26) but have not characterized long-term use of
these therapies after coronary revascularization. Studies that
did examine long-term medication use post-revascularization
have usually done so in a cross-sectional manner, examining
use at a single point in time, such as at 6 or 12 months. In
1 large national community-based claims analysis of medi-
cation use after acute coronary syndrome, Lee et al. (27)
found rates of statin (73%), beta-blocker (73%), and ACEI/
ARB (62%) use at 12 months after discharge, rates that were
lower than those found in our study. Our study adds to the
published data by measuring post-discharge medication use
continuously over the first year after revascularization.
In spite of the large body of published data on use of
medications for secondary prevention after revasculariza-
tion, few studies have compared the rate of medication use
after CABG with the rate after PCI. In 1 such study,
Hiratzka et al. (28) examined the use of medications at
discharge after CABG, PCI, or medically managed acute
coronary syndrome in hospitals enrolled in the American
Heart Association Get With the Guidelines program. They
also found that patients who received CABG had lower
rates of prescriptions at discharge than patients who re-
ceived PCI: 57.3% versus 74.0% for ACEI; 90.8% versus
91.0% for beta-blockers, and 77.4% versus 89.2% for lipid-
lowering medication (p  0.0001 for all comparisons). The
difference in use of ACEI and statins in their study
remained significant after multivariable adjustment for clin-
ical characteristics. They did not, however, have any data onmedication use after discharge and were unable to measure
adherence in subsequent follow-up.
Study limitations. First, we relied on pharmacy dispensing
data to ascertain the timing of prescription refills and to
estimate adherence. We do not have data on whether
patients actually took their medications as prescribed. If
some patients were advised to “split pills,” this could affect
the calculated MPRs, because adherent patients would refill
prescriptions less frequently. Nor do we have data on
prescriptions filled at outside pharmacies, although prior
surveys of health plan members show over 95% use of Kaiser
Permanente pharmacies to obtain medications for chronic
conditions. Second, we do not have access to detailed
clinical data on reasons for not prescribing medications
initially or for discontinuing medications during follow-up.
Although we have no reason to believe that patient toler-
ance to medications would vary by revascularization
method, unobserved differences between patients who un-
derwent CABG or PCI could account for the observed
differences in adherence rates. Third, we do not have
information on some clinical characteristics, such as anemia
or left ventricular ejection fraction, which might have
affected initial prescription of medications or subsequent
adherence. Fourth, we do not have data on patient socio-
economic status, the distance to a Kaiser Permanente
pharmacy, or the specialty of physician who saw the patient
in follow-up, all of which might have affected long-term
adherence to medications. Finally, the last year of patient
entry into this study was 2007, and medication use might
have further improved since then.
Conclusions
Our study suggests that patients who receive CABG are less
likely than patients who receive PCI to fill initial prescrip-
tions for selected cardioprotective medications and to re-
main adherent to these medications during the first year
after revascularization. Although the absolute differences in
medication use in this study were small, our findings
nevertheless suggest that there might be systematic factors
after CABG and PCI that contribute to lower medication
use after CABG. Addressing these differences might pro-
vide an opportunity to further improve the quality of care
after coronary revascularization. Future research should
examine the factors that predict poorer adherence to car-
dioprotective and should test interventions to improve both
the initial prescription and long-term adherence to proven
medications for secondary prevention (29).
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